A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy

被引:80
作者
Ruan, HJ
Su, H
Hu, L
Lamborn, KR
Kan, YW
Deen, DF [1 ]
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA
来源
NEOPLASIA | 2001年 / 3卷 / 03期
关键词
hypoxia; brain tumor cells; hypoxia-responsive element; adeno-associated virus; gene therapy;
D O I
10.1038/sj.neo.7900157
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The presence of hypoxic cells in human brain tumors is an important factor leading to resistance to radiation therapy. However, this physiological difference between normal tissues and tumors also provides the potential for designing cancer-specific gene therapy. We compared the increase of gene expression under anoxia (<0.01% oxygen) produced by 3, 6, and 9 copies of hypoxia-responsive elements (HRE) from the erythropoietin gene (Epo), which are activated through the transcriptional complex hypoxia-inducible factor 1 (HIF-1). Under anoxic conditions, nine copies of HIRE (9XHRE) yielded 27- to 37-fold of increased gene expression in U-251 MG and U-87 MG human brain tumor cell lines. Under the less hypoxic conditions of 0.3% and 1% oxygen, gene activation by 9XHRE increased expression 11- to 18-fold in these cell lines. To generate a recombinant adeno-associated virus (rAAV) in which the transgene can be regulated by hypoxia, we inserted the DNA fragment containing 9XHRE and the LacZ reporter gene into an AAV vector. Under anoxic conditions, this vector produced 79- to 110-fold increase in gene expression. We believe this hypoxia-regulated rAAV vector will provide a useful delivery vehicle for cancer-specific gene therapy.
引用
收藏
页码:255 / 263
页数:9
相关论文
共 36 条
[1]  
[Anonymous], CANC RES
[2]   An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer [J].
Binley, K ;
Iqball, S ;
Kingsman, A ;
Kingsman, S ;
Naylor, S .
GENE THERAPY, 1999, 6 (10) :1721-1727
[3]   Characterization of physiologically regulated vectors for the treatment of ischemic disease [J].
Boast, K ;
Binley, K ;
Iqball, S ;
Price, T ;
Spearman, H ;
Kingsman, S ;
Kingsman, A ;
Naylor, S .
HUMAN GENE THERAPY, 1999, 10 (13) :2197-2208
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
Brizel DM, 1996, CANCER RES, V56, P941
[6]  
Brown JM, 1999, CANCER RES, V59, P5863
[7]   Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies [J].
Brown, JM .
MOLECULAR MEDICINE TODAY, 2000, 6 (04) :157-162
[8]   CONSTITUTIONAL P53 MUTATIONS ASSOCIATED WITH BRAIN-TUMORS IN YOUNG-ADULTS [J].
CHEN, PC ;
IAVARONE, A ;
FICK, J ;
EDWARDS, M ;
PRADOS, M ;
ISRAEL, MA .
CANCER GENETICS AND CYTOGENETICS, 1995, 82 (02) :106-115
[9]   Targeting gene expression to hypoxic tumor cells [J].
Dachs, GU ;
Patterson, AV ;
Firth, JD ;
Ratcliffe, PJ ;
Townsend, KMS ;
Stratford, IJ ;
Harris, AL .
NATURE MEDICINE, 1997, 3 (05) :515-520
[10]   Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [J].
Graeber, TG ;
Osmanian, C ;
Jacks, T ;
Housman, DE ;
Koch, CJ ;
Lowe, SW ;
Giaccia, AJ .
NATURE, 1996, 379 (6560) :88-91